JP2009510133A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510133A5
JP2009510133A5 JP2008533836A JP2008533836A JP2009510133A5 JP 2009510133 A5 JP2009510133 A5 JP 2009510133A5 JP 2008533836 A JP2008533836 A JP 2008533836A JP 2008533836 A JP2008533836 A JP 2008533836A JP 2009510133 A5 JP2009510133 A5 JP 2009510133A5
Authority
JP
Japan
Prior art keywords
composition
composition according
epitope
antigen
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008533836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510133A (ja
JP5528703B2 (ja
Filing date
Publication date
Priority claimed from CA002523032A external-priority patent/CA2523032A1/en
Application filed filed Critical
Publication of JP2009510133A publication Critical patent/JP2009510133A/ja
Publication of JP2009510133A5 publication Critical patent/JP2009510133A5/ja
Application granted granted Critical
Publication of JP5528703B2 publication Critical patent/JP5528703B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008533836A 2005-10-07 2006-10-05 がん治療のためのビヒクルとして連続的疎水性相を含む担体におけるリポソームの使用 Expired - Fee Related JP5528703B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CA002523032A CA2523032A1 (en) 2005-10-07 2005-10-07 Vaccines for cancer therapy
CA2,523,032 2005-10-07
CA2,533,705 2006-01-13
CA002533705A CA2533705A1 (en) 2005-10-07 2006-01-13 Use of liposomes in a water-in-oil emulsion or in a continuous hydrophobic carrier as a vehicle for cancer treatment
CA002542212A CA2542212A1 (en) 2005-10-07 2006-04-07 Use of liposomes in a water-in-oil emulsion or in a continuous hydrophobic carrier as a vehicle for cancer treatment
CA2,542,212 2006-04-07
US80657306P 2006-07-05 2006-07-05
US60/806,573 2006-07-05
PCT/CA2006/001640 WO2007041832A1 (en) 2005-10-07 2006-10-05 Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment

Publications (3)

Publication Number Publication Date
JP2009510133A JP2009510133A (ja) 2009-03-12
JP2009510133A5 true JP2009510133A5 (enExample) 2009-11-26
JP5528703B2 JP5528703B2 (ja) 2014-06-25

Family

ID=37942250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533836A Expired - Fee Related JP5528703B2 (ja) 2005-10-07 2006-10-05 がん治療のためのビヒクルとして連続的疎水性相を含む担体におけるリポソームの使用

Country Status (8)

Country Link
US (3) US20090297593A1 (enExample)
EP (1) EP1948225B1 (enExample)
JP (1) JP5528703B2 (enExample)
CN (1) CN101282742B (enExample)
AU (1) AU2006301891B2 (enExample)
CA (4) CA2523032A1 (enExample)
ES (1) ES2451599T3 (enExample)
WO (1) WO2007041832A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038175A1 (en) 2000-11-07 2002-05-16 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
BRPI0817484B1 (pt) * 2007-10-03 2021-08-17 Immunovaccine Technologies Inc Composição de vacina sem água, processo de produção e o uso dos mesmos
CA2723918C (en) * 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
EP3228321B1 (en) * 2011-09-13 2019-04-10 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
IN2014CN02581A (enExample) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
CN103961696A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
CA2908042C (en) 2013-03-27 2023-01-31 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
US20170137458A1 (en) * 2014-07-02 2017-05-18 David Lembo Oxysterols for use in the treatment and prevention of diseases caused by viruses
WO2016021605A1 (ja) * 2014-08-04 2016-02-11 日東電工株式会社 Ｃｔｌのアポトーシスを抑制するまたｃｔｌの誘導抑制を阻害するワクチン医薬組成物
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
WO2016176761A1 (en) * 2015-05-01 2016-11-10 Immunovaccine Technologies Inc., Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
CN108430505A (zh) 2015-11-18 2018-08-21 免疫疫苗技术有限公司 包括聚肌胞苷酸多核苷酸佐剂和基于脂质的佐剂的辅助系统以及无水疫苗组合物
WO2017190242A1 (en) 2016-05-04 2017-11-09 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
CA3038155A1 (en) * 2016-09-27 2018-04-05 Immunovaccine Technologies Inc. Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects
MX2019007611A (es) * 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
CN118453840A (zh) 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN112188887A (zh) * 2018-03-20 2021-01-05 免疫疫苗技术公司 用于将活性剂和免疫调节剂靶向递送至淋巴结的方法和组合物
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CN116531498A (zh) * 2023-04-11 2023-08-04 金宇保灵生物药品有限公司 一种免疫增强剂、制备方法及其应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5897873A (en) * 1984-04-12 1999-04-27 The Liposome Company, Inc. Affinity associated vaccine
US6093406A (en) * 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5015476A (en) * 1989-08-11 1991-05-14 Paravax, Inc. Immunization implant and method
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
JP2502234B2 (ja) 1990-06-29 1996-05-29 カイロン コーポレイション リポソ―ム含有ワクチン組成物
ATE189818T1 (de) * 1990-12-12 2000-03-15 Univ Queensland Papillomavirusuntereinheit-impfstoff
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
CA2137363C (en) 1992-06-05 1999-06-15 Robert Brown Use of zona pellucida glycoproteins for immunocontraception
USRE37224E1 (en) * 1992-06-05 2001-06-12 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and adjuvant
US5736141A (en) * 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
JPH06247842A (ja) * 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法
AU702517B2 (en) * 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
US20050049197A1 (en) * 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
JP3872813B2 (ja) * 1994-05-18 2007-01-24 エス．ピー．アイ． シンセティック ペプチデス インコーポレイテッド ヘテロダイマーポリペプチド免疫原キャリア組成物および方法
US5637300A (en) * 1994-08-03 1997-06-10 Dunbar; Bonnie S. Contraceptive vaccine comprising a glycosylated 55 kD zona pellucida protein immunogen and method of use of the same in contraception
US6355256B1 (en) * 1994-09-30 2002-03-12 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
WO1996040066A1 (en) * 1995-06-07 1996-12-19 The Governors Of The University Of Alberta A METHOD FOR ELICITING A Th1-SPECIFIC IMMUNE RESPONSE
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US7019112B1 (en) * 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
WO1998053799A2 (en) * 1997-05-28 1998-12-03 Jenner Biotherapies, Inc. Immunogenic compositions
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
AU8921698A (en) * 1997-08-29 1999-03-16 Human Genome Sciences, Inc. Follistatin-3
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6183746B1 (en) * 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
JP2002510644A (ja) * 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
US6588671B2 (en) * 1998-04-09 2003-07-08 Dcard, Inc. Positioning of a recording head for a data storage device
US6472375B1 (en) * 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6406719B1 (en) * 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
EP1013268A1 (en) * 1998-06-30 2000-06-28 Rohto Pharmaceutical Co., Ltd. Compositions containing liposomes and/or emulsions and process for the preparation thereof
US20050084524A1 (en) * 1998-09-30 2005-04-21 Alza Corporation Method for potentiating activity of a chemotherapeutic drug
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
AU1765300A (en) 1998-12-22 2000-07-12 Dalhousie University Compositions and methods for reducing or preventing fertilization in fish and birds
US6670195B1 (en) * 1999-05-26 2003-12-30 New York University Mutant genes in Familial British Dementia and Familial Danish Dementia
US6534064B1 (en) * 1999-10-13 2003-03-18 Chiron Corporation Stabilized protein particles for inducing cellular immune responses
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
WO2002038175A1 (en) * 2000-11-07 2002-05-16 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
EP1343476B1 (en) 2000-12-01 2008-05-28 Biomira Inc. Preparation of large liposomes by infusion into peg
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
JPWO2003009870A1 (ja) * 2001-07-25 2004-11-11 三菱ウェルファーマ株式会社 乳癌治療薬
US6814969B2 (en) * 2001-07-31 2004-11-09 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
US7056515B2 (en) * 2002-02-08 2006-06-06 Immunovaccine Technologies Inc. Antigens for immunocontraception
EP1474447A2 (en) 2002-02-08 2004-11-10 Immunovaccine Technologies Inc. Antigens for immunocontraception
AU2003277865B2 (en) * 2002-06-25 2008-08-21 City Of Hope Adjuvant-free peptide vaccine
JP2004051238A (ja) 2002-07-16 2004-02-19 Canon Inc シート搬送装置及び画像形成装置
US6586671B1 (en) 2002-08-06 2003-07-01 Interrail Signal, Inc. Above ground track signal terminal apparatus
AU2003268087A1 (en) * 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
EP1393720A1 (en) * 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
DE10249401A1 (de) * 2002-10-23 2004-05-13 Bernina Biosystems Gmbh Liposomen formende Zusammensetzung
US20050158375A1 (en) * 2002-11-15 2005-07-21 Toshikiro Kimura Pharmaceutical composition containing liposomes for treating cancer
EP1583548A4 (en) * 2002-12-10 2007-10-17 Epimmune Inc PEPTIDES DIRECTED AGAINST ANTIGENS ASSOCIATED WITH HLA-A1, A2 -A3, -A24, -B7, AND -B44 TUMORS AND COMPOSITIONS
ES2381309T3 (es) * 2002-12-23 2012-05-25 Dynavax Technologies Corporation Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos
WO2004089981A2 (en) * 2003-04-02 2004-10-21 Board Of Regents, The University Of Texas System Antitumor effect of mutant bik
PT1620456E (pt) * 2003-04-18 2014-04-15 Biotech Synergy Inc Péptidos antigénicos hla-a2 associados a tumor e suas composições
JP2007504149A (ja) * 2003-08-26 2007-03-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 抗癌ワクチン
US20050220781A1 (en) * 2003-09-04 2005-10-06 Duen-Hwa Yan IFIX, a novel HIN-200 protein, for cancer therapy
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
EP1711208A2 (en) * 2004-01-28 2006-10-18 Curix APS Conjugates of amyloid proteins as vaccines for amyloid-related diseases
EP1737966B1 (en) * 2004-04-02 2012-05-09 Board of Regents, The University of Texas System Cancer specific promoters
DE602005018043D1 (de) * 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy

Similar Documents

Publication Publication Date Title
JP2009510133A5 (enExample)
Kersten et al. Liposomes and ISCOMS
Guan et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses
Razazan et al. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model
Shariat et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
CN1096851C (zh) 疫苗组合物佐剂
US20210322573A1 (en) Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
CN101282742B (zh) 脂质体在含连续疏水相的载体中作为癌症治疗媒介物的应用
JP2014503475A5 (enExample)
Nakamura et al. Incorporation of polyinosine–polycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine-modified liposomes encapsulating antigen, but not by octaarginine-modified antigen complex
JP2022116265A (ja) 両親媒性化合物、新生抗原及び疎水性担体を含むワクチン組成物、並びにその使用方法
HRP20170433T1 (hr) Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
WO2016046060A1 (en) Stable formulations of lipids and liposomes
CN111905099A (zh) 用于改善存活蛋白疫苗在癌症治疗中的功效的方法
Farzad et al. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer
Qiao et al. A MnAl double adjuvant nanovaccine to induce strong humoral and cellular immune responses
JP2013121977A5 (enExample)
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
JP2013505201A5 (enExample)
JP2020506938A (ja) イミダゾキノリン系物質を含むナノエマルジョン及びその用途
Du et al. MUC1 specific immune responses enhanced by coadministration of liposomal DDA/MPLA and lipoglycopeptide
Ahmad et al. Liposomes and niosomes for targeted drug and gene delivery systems
JP2006528650A5 (enExample)
Lin et al. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice
Barati et al. AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer